AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$PTCT

Boulding Mark Elliott sold $133K of PTCT

Boulding Mark Elliott (EXEC. VP AND CLO) sold 2,073 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $64.06 ($64.03–$64.16, $0.13M total) across 2 trades over 2026-10-05 to 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boulding Mark Elliott
Published Oct 7, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Bearish
medium confidence
Mentioned
$PTCT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTBearishLow
01

Why it matters

The disclosed sale is modest in size but may influence short‑term trading sentiment for PTCT.

02

Market read

A small insider sell by a senior officer, likely to generate limited but measurable downside pressure.

03

What to watch

Potential upcoming clinical data could offset any negative sentiment from the insider sell.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering insight into insider sentiment.

Company-level read

Ticker impact

$PTCTBearishMedium confidence
Context

SEC Form 4 disclosed executive Mark Elliott sold 2,073 shares of PTC Therapeutics for $132,791 via a 10b5‑1 plan.

Expected impact

likely modest downward pressure as market prices in the insider sell

Evidence & confidence

The sale is small ($133K) but executed by a senior officer; such transactions often lead to short‑term sell‑side bias.

Market effects

Sector

minimal impact on biotech sector

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Executive
    Mark Elliott

    Executive Vice President and Chief Legal Officer of PTC Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

SEP 22
$PTCTMedAI 8/10

Cantor raises PTC Therapeutics stock price target on Fabry deal

Cantor Fitzgerald raised its price target for PTC Therapeutics (NASDAQ:PTCT) to $137 from $130, citing the company's acquisition of ST-920, a gene therapy for Fabry disease. The new target suggests over 100% upside from the current stock price. PTC reported strong Q2 2026 earnings, beating expectations and raising its full-year revenue outlook. The company expects to be profitable this year with an EPS forecast of $2.00.

investing.com2 min
AUG 27
$PTCTMedAI 8/10

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

simplywall.st3 min
AUG 24
$PTCTMedAI 8/10

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

morningstar.com2 min